Literature DB >> 23028058

Immunity to the conserved influenza nucleoprotein reduces susceptibility to secondary bacterial infections.

Laura Haynes1, Frank M Szaba, Sheri M Eaton, Lawrence W Kummer, Paula A Lanthier, Ashlee H Petell, Debra K Duso, Deyan Luo, Jr-Shiuan Lin, Julie S Lefebvre, Troy D Randall, Lawrence L Johnson, Jacob E Kohlmeier, David L Woodland, Stephen T Smiley.   

Abstract

Influenza causes >250,000 deaths annually in the industrialized world, and bacterial infections frequently cause secondary illnesses during influenza outbreaks, including pneumonia, bronchitis, sinusitis, and otitis media. In this study, we demonstrate that cross-reactive immunity to mismatched influenza strains can reduce susceptibility to secondary bacterial infections, even though this fails to prevent influenza infection. Specifically, infecting mice with H3N2 influenza before challenging with mismatched H1N1 influenza reduces susceptibility to either Gram-positive Streptococcus pneumoniae or Gram-negative Klebsiella pneumoniae. Vaccinating mice with the highly conserved nucleoprotein of influenza also reduces H1N1-induced susceptibility to lethal bacterial infections. Both T cells and Abs contribute to defense against influenza-induced bacterial diseases; influenza cross-reactive T cells reduce viral titers, whereas Abs to nucleoprotein suppress induction of inflammation in the lung. These findings suggest that nonneutralizing influenza vaccines that fail to prevent influenza infection may nevertheless protect the public from secondary bacterial diseases when neutralizing vaccines are not available.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23028058      PMCID: PMC3490014          DOI: 10.4049/jimmunol.1201916

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans.

Authors:  Tom M Wilkinson; Chris K F Li; Cecilia S C Chui; Arthur K Y Huang; Molly Perkins; Julia C Liebner; Rob Lambkin-Williams; Anthony Gilbert; John Oxford; Ben Nicholas; Karl J Staples; Tao Dong; Daniel C Douek; Andrew J McMichael; Xiao-Ning Xu
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

2.  Live attenuated influenza vaccine (LAIV) impacts innate and adaptive immune responses.

Authors:  Paula A Lanthier; Gail E Huston; Amy Moquin; Sheri M Eaton; Frank M Szaba; Lawrence W Kummer; Micheal P Tighe; Jacob E Kohlmeier; Patrick J Blair; Michael Broderick; Stephen T Smiley; Laura Haynes
Journal:  Vaccine       Date:  2011-08-02       Impact factor: 3.641

3.  Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance.

Authors:  Mark W Lamere; Amy Moquin; F Eun-Hyung Lee; Ravi S Misra; Patrick J Blair; Laura Haynes; Troy D Randall; Frances E Lund; Denise A Kaminski
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

4.  Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus.

Authors:  Mark W LaMere; Ho-Tak Lam; Amy Moquin; Laura Haynes; Frances E Lund; Troy D Randall; Denise A Kaminski
Journal:  J Immunol       Date:  2011-02-25       Impact factor: 5.422

5.  Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway.

Authors:  Robert M Anthony; Toshihiko Kobayashi; Fredrik Wermeling; Jeffrey V Ravetch
Journal:  Nature       Date:  2011-06-19       Impact factor: 49.962

6.  Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections.

Authors:  Keer Sun; Jianqiang Ye; Daniel R Perez; Dennis W Metzger
Journal:  J Immunol       Date:  2010-12-15       Impact factor: 5.422

Review 7.  Cross-protective immunity to influenza A viruses.

Authors:  Suzanne L Epstein; Graeme E Price
Journal:  Expert Rev Vaccines       Date:  2010-11       Impact factor: 5.217

8.  A new synthesis for antibody-mediated immunity.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  Nat Immunol       Date:  2011-12-16       Impact factor: 25.606

9.  Platelet-activating factor receptor plays a role in lung injury and death caused by Influenza A in mice.

Authors:  Cristiana C Garcia; Remo C Russo; Rodrigo Guabiraba; Caio T Fagundes; Rafael B Polidoro; Luciana P Tavares; Ana Paula C Salgado; Geovanni D Cassali; Lirlândia P Sousa; Alexandre V Machado; Mauro M Teixeira
Journal:  PLoS Pathog       Date:  2010-11-04       Impact factor: 6.823

Review 10.  Pathogenic responses among young adults during the 1918 influenza pandemic.

Authors:  G Dennis Shanks; John F Brundage
Journal:  Emerg Infect Dis       Date:  2012-02       Impact factor: 6.883

View more
  22 in total

1.  Influenza-induced type I interferon enhances susceptibility to gram-negative and gram-positive bacterial pneumonia in mice.

Authors:  Benjamin Lee; Keven M Robinson; Kevin J McHugh; Erich V Scheller; Sivanarayana Mandalapu; Chen Chen; Y Peter Di; Michelle E Clay; Richard I Enelow; Patricia J Dubin; John F Alcorn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-05-22       Impact factor: 5.464

2.  Attenuation of Influenza A Virus Disease Severity by Viral Coinfection in a Mouse Model.

Authors:  Andres J Gonzalez; Emmanuel C Ijezie; Onesmo B Balemba; Tanya A Miura
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

Review 3.  Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.

Authors:  Jean-Louis Excler; Julie Ake; Merlin L Robb; Jerome H Kim; Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2014-06-11

4.  Vaccination mitigates influenza-induced muscular declines in aged mice.

Authors:  Spencer R Keilich; Erica C Lorenzo; Blake L Torrance; Andrew G Harrison; Jenna M Bartley; Laura Haynes
Journal:  Geroscience       Date:  2020-05-29       Impact factor: 7.713

5.  Lethal coinfection of influenza virus and Streptococcus pneumoniae lowers antibody response to influenza virus in lung and reduces numbers of germinal center B cells, T follicular helper cells, and plasma cells in mediastinal lymph Node.

Authors:  Yuet Wu; Wenwei Tu; Kwok-Tai Lam; Kin-Hung Chow; Pak-Leung Ho; Yi Guan; Joseph S Malik Peiris; Yu-Lung Lau
Journal:  J Virol       Date:  2014-11-26       Impact factor: 5.103

Review 6.  Panel 6: Vaccines.

Authors:  Melinda M Pettigrew; Mark R Alderson; Lauren O Bakaletz; Stephen J Barenkamp; Anders P Hakansson; Kevin M Mason; Johanna Nokso-Koivisto; Janak Patel; Stephen I Pelton; Timothy F Murphy
Journal:  Otolaryngol Head Neck Surg       Date:  2017-04       Impact factor: 3.497

7.  Limited Efficacy of Antibacterial Vaccination Against Secondary Serotype 3 Pneumococcal Pneumonia Following Influenza Infection.

Authors:  Dennis W Metzger; Yoichi Furuya; Sharon L Salmon; Sean Roberts; Keer Sun
Journal:  J Infect Dis       Date:  2015-02-03       Impact factor: 5.226

Review 8.  Vaccine strategies to enhance immune responses in the aged.

Authors:  Julie S Lefebvre; Laura Haynes
Journal:  Curr Opin Immunol       Date:  2013-06-10       Impact factor: 7.486

9.  CD4+ T cells provide intermolecular help to generate robust antibody responses in vaccinia virus-vaccinated humans.

Authors:  Liusong Yin; J Mauricio Calvo-Calle; John Cruz; Frances K Newman; Sharon E Frey; Francis A Ennis; Lawrence J Stern
Journal:  J Immunol       Date:  2013-05-10       Impact factor: 5.422

10.  Influenza A induced cellular signal transduction pathways.

Authors:  Paul Michael; Danielle Brabant; Farag Bleiblo; Chilakamarti V Ramana; Michael Rutherford; Sandhya Khurana; T C Tai; Anand Kumar; Aseem Kumar
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.